Jyoti Malhotra

Jyoti Malhotra is an Indian travel vlogger who ran the YouTube channel ''Travel with JO''.

She was arrested in May 2025 under the under the Official Secrets Act amid the 2025 India–Pakistan conflict. She is accused of espionage, passing sensitive information to operatives of Pakistan’s Inter-Services Intelligence (ISI). Her arrest drew widespread national media coverage. Provided by Wikipedia
Showing 1 - 20 results of 20 for search 'Jyoti Malhotra', query time: 0.07s Refine Results
  1. 1
    Molecular and Genetic Epidemiology of Cancer in Low- and Medium-Income Countries

    Molecular and Genetic Epidemiology of Cancer in Low- and Medium-Income Countries by Jyoti Malhotra

    Published 2014-12-01
    Get full text
    Article
  2. 2
    Golodirsen restores DMD transcript imbalance in Duchenne Muscular Dystrophy patient muscle cells

    Golodirsen restores DMD transcript imbalance in Duchenne Muscular Dystrophy patient muscle cells by Rachele Rossi, Silvia Torelli, Marc Moore, Pierpaolo Ala, Jennifer Morgan, Jyoti Malhotra, Francesco Muntoni

    Published 2024-11-01
    Get full text
    Article
  3. 3
    Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes

    Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes by Paul Markowitz, Malini Patel, Roman Groisberg, Joseph Aisner, Salma K. Jabbour, Subhajyoti De, Shridar Ganesan, Jyoti Malhotra

    Published 2020-01-01
    Get full text
    Article
  4. 4
    602 A phase I trial of atezolizumab and varlilumab in combination with radiation in patients with metastatic non-small cell lung cancer (NSCLC)

    602 A phase I trial of atezolizumab and varlilumab in combination with radiation in patients with metastatic non-small cell lung cancer (NSCLC) by Yong Lin, Jyoti Malhotra, Salma K Jabbour, Michael J Yellin, Malini Patel, Emmanuel Zachariah, Curtis Krier, Ankit Saxena

    Published 2023-11-01
    Article
  5. 5
    Non-Genetic Intra-Tumor Heterogeneity Is a Major Predictor of Phenotypic Heterogeneity and Ongoing Evolutionary Dynamics in Lung Tumors

    Non-Genetic Intra-Tumor Heterogeneity Is a Major Predictor of Phenotypic Heterogeneity and Ongoing Evolutionary Dynamics in Lung Tumors by Anchal Sharma, Elise Merritt, Xiaoju Hu, Angelique Cruz, Chuan Jiang, Halle Sarkodie, Zhan Zhou, Jyoti Malhotra, Gregory M. Riedlinger, Subhajyoti De

    Published 2019-11-01
    Get full text
    Article
  6. 6
    603 Phase II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): big ten cancer research consortium (BTCRC-LUN17–127) study

    603 Phase II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): big ten cancer research consortium (BTCRC-LU... by Jyoti Malhotra, Alberto Chiappori, Salma K Jabbour, Chunxia Chen, Naomi Fujioka, Nasser H Hanna, Lawrence E Feldman, Malini Patel, Dirk Moore

    Published 2023-11-01
    Article
  7. 7
    A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer

    A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer by Prakash Kulkarni, Atish Mohanty, Sravani Ramisetty, Herbert Duvivier, Ajaz Khan, Sagun Shrestha, Tingting Tan, Amartej Merla, Michelle El-Hajjaoui, Jyoti Malhotra, Sharad Singhal, Ravi Salgia

    Published 2023-10-01
    Get full text
    Article
  8. 8
    MyoD-induced reprogramming of human fibroblasts and urinary stem cells in vitro: protocols and their applications

    MyoD-induced reprogramming of human fibroblasts and urinary stem cells in vitro: protocols and their applications by Rachele Rossi, Rachele Rossi, Silvia Torelli, Silvia Torelli, Pierpaolo Ala, Pierpaolo Ala, William Weston, William Weston, Jennifer Morgan, Jennifer Morgan, Jyoti Malhotra, Francesco Muntoni, Francesco Muntoni

    Published 2023-05-01
    Get full text
    Article
  9. 9
    Atherogenic low density lipoprotein phenotype in long-term survivors of childhood acute lymphoblastic leukemia

    Atherogenic low density lipoprotein phenotype in long-term survivors of childhood acute lymphoblastic leukemia by Jyoti Malhotra, Emily S. Tonorezos, Marina Rozenberg, Gloria L. Vega, Charles A. Sklar, Joanne Chou, Chaya S. Moskowitz, Debra A. Eshelman-Kent, Peter Janiszewski, Robert Ross, Kevin C. Oeffinger

    Published 2012-12-01
    Get full text
    Article
  10. 10
    Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)

    Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504) by Saad A. Khan, MD, Zhuoxin Sun, PhD, Suzanne Dahlberg, PhD, Jyoti Malhotra, MD, Roger Keresztes, MD, Chukwuemeka Ikpeazu, MD, Patrick Ma, MD, Suresh S. Ramalingam, MD, Rathi Pillai, MD

    Published 2021-05-01
    Get full text
    Article
  11. 11
    A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC

    A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC by Jyoti Malhotra, MD, MPH, Yong Lin, PhD, Malini Patel, MD, Michael J. Yellin, MD, Emmanuel Zachariah, PhD, Curtis Krier, PhD, Ankit Saxena, PhD, Salma K. Jabbour, MD

    Published 2024-08-01
    Get full text
    Article
  12. 12
    Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution

    Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution by Nikhil Yegya-Raman, MD, Joseph Aisner, MD, Sinae Kim, PhD, Mutlay Sayan, MD, Diana Li, BA, John Langenfeld, MD, Malini Patel, MD, Jyoti Malhotra, MD, MPH, Salma K. Jabbour, MD

    Published 2019-07-01
    Get full text
    Article
  13. 13
    Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer

    Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer by Jyoti Malhotra, Janice M Mehnert, Ann W Silk, Roman Groisberg, Shang-Jui Wang, Karishma Khullar, Sinae Kim, Nikhil Yegya-Raman, Samuel H Crayton, John L Nosher, Michael A Gentile, Salma K Jabbour

    Published 2020-10-01
    Get full text
    Article
  14. 14
    A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors

    A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors by Ann W. Silk, Biren Saraiya, Roman Groisberg, Nancy Chan, Kristen Spencer, Eugenia Girda, Weichung Shih, Marisa Palmeri, Tracie Saunders, Robert M. Berman, Vlad Coric, Suzie Chen, Andrew Zloza, Joshua Vieth, Janice M. Mehnert, Jyoti Malhotra

    Published 2022-07-01
    Get full text
    Article
  15. 15
    The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy

    The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy by Dominic Scaglioni, Francesco Catapano, Matthew Ellis, Silvia Torelli, Darren Chambers, Lucy Feng, Matthew Beck, Caroline Sewry, Mauro Monforte, Shawn Harriman, Erica Koenig, Jyoti Malhotra, Linda Popplewell, Michela Guglieri, Volker Straub, Eugenio Mercuri, Laurent Servais, Rahul Phadke, Jennifer Morgan, Francesco Muntoni

    Published 2021-01-01
    Get full text
    Article
  16. 16
    O19: Integrated analyses of data from clinical trials of delandistrogene moxeparvovec gene therapy in DMD*

    O19: Integrated analyses of data from clinical trials of delandistrogene moxeparvovec gene therapy in DMD* by Erin O’Rourke, Crystal Proud, Craig Zaidman, Perry B. Shieh, Craig McDonald, John W. Day, Stefanie Mason, Maitea Guridi, Lixin Han, Lixi Yu, Carol Reid, Eddie Darton, Christoph Wandel, James Richardson, Jyoti Malhotra, Teji Singh, Louise Rodino-Klapac, Jerry Mendell

    Published 2023-01-01
    Get full text
    Article
  17. 17
    Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors

    Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors by Vrushank Bhatt, Taijin Lan, Wenping Wang, Jerry Kong, Eduardo Cararo Lopes, Jianming Wang, Khoosheh Khayati, Akash Raju, Michael Rangel, Enrique Lopez, Zhixian Sherrie Hu, Xuefei Luo, Xiaoyang Su, Jyoti Malhotra, Wenwei Hu, Sharon R. Pine, Eileen White, Jessie Yanxiang Guo

    Published 2023-01-01
    Get full text
    Article
  18. 18
    Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC

    Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC by Tamara Mirzapoiazova, Liz Tseng, Bolot Mambetsariev, Haiqing Li, Chih-Hong Lou, Alex Pozhitkov, Sravani Keerthi Ramisetty, Sangkil Nam, Isa Mambetsariev, Brian Armstrong, Jyoti Malhotra, Leonidas Arvanitis, Mohd Wasim Nasser, Surinder K. Batra, Steven T. Rosen, Deric L. Wheeler, Sharad S. Singhal, Prakash Kulkarni, Ravi Salgia

    Published 2024-06-01
    Get full text
    Article
  19. 19
    A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)

    A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782) by Ticiana A. Leal, Marina N. Sharifi, Nancy Chan, Robert Wesolowski, Anita A. Turk, Justine Y. Bruce, Ruth M. O'Regan, Jens Eickhoff, Lisa M. Barroilhet, Jyoti Malhotra, Janice Mehnert, Eugenia Girda, Elizabeth Wiley, Natalie Schmitz, Shannon Andrews, Glenn Liu, Kari B. Wisinski

    Published 2022-11-01
    Get full text
    Article
  20. 20
    Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

    Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration by Mark N. Stein, Jyoti Malhotra, Rohinton S. Tarapore, Usha Malhotra, Ann W. Silk, Nancy Chan, Lorna Rodriguez, Joseph Aisner, Robert D. Aiken, Tina Mayer, Bruce G. Haffty, Jenna H. Newman, Salvatore M. Aspromonte, Praveen K. Bommareddy, Ricardo Estupinian, Charles B. Chesson, Evita T. Sadimin, Shengguo Li, Daniel J. Medina, Tracie Saunders, Melissa Frankel, Aparna Kareddula, Sherrie Damare, Elayne Wesolowsky, Christian Gabel, Wafik S. El-Deiry, Varun V. Prabhu, Joshua E. Allen, Martin Stogniew, Wolfgang Oster, Joseph R. Bertino, Steven K. Libutti, Janice M. Mehnert, Andrew Zloza

    Published 2019-05-01
    Get full text
    Article

Search Tools: